LLY vs RYTM
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. RYTM: Rhythm Pharmaceuticals is a biopharmaceutical company specializing in precision therapies for rare genetic and neuroendocrine disorders characterized by severe obesity and hyperphagia.
Side-by-side fundamentals
| Metric | LLY | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $1,215.02 | $112.85 | |
| Market cap as of 2026-08-12 | $1.14T | $7.8B | |
| P/E as of 2026-08-12 | 42.17 | n/a | |
| PEG as of 2026-08-12 | 1.48 | -3.21 | RYTM lower |
| Net margin as of 2026-08-12 | +33.5% | -85.6% | LLY higher |
| Gross margin as of 2026-08-12 | +83.4% | +70.9% | LLY higher |
| Operating margin as of 2026-08-12 | +42.2% | -83.6% | LLY higher |
| ROE as of 2026-08-12 | +92.6% | -80.5% | LLY higher |
| ROA as of 2026-08-12 | +22.0% | -44.0% | LLY higher |
| Debt / equity as of 2026-08-12 | 1.62 | 0.49 | RYTM lower |
| Revenue growth (YoY) as of 2026-08-12 | +49.6% | +53.5% | RYTM higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +100.2% | RYTM higher |
| Dividend yield as of 2026-08-12 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-12 | 0.46 | 2.00 | |
| 1-year return as of 2026-08-11 close | +91.3% | +19.7% | LLY higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.